📰 P Gp Substrates News

P Gp Substrates News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from P Gp Substrates. Real-time updates on events, politics, business and more.

Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing's Syndrome | Illinois

January 31, 2022

CHICAGO--(BUSINESS WIRE)--Jan 31, 2022--

United States Lindsay Rocco Allison Wey Xeris Biopharma Strongbridge Biopharma Xeris Careconnection

Source: wsiltv.com

PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome

January 13, 2022

/PRNewswire/ -- PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc.,...

United States Rob Snyder Xeris Biopharma Allyson Ayoob Xeris Pharmaceuticals Inc Accreditation Commission For Health Care

Source: prnewswire.com

PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome

January 13, 2022

/PRNewswire/ -- PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc.,...

United States Rob Snyder Xeris Biopharma Allyson Ayoob Xeris Pharmaceuticals Inc Accreditation Commission For Health Care

Source: prnewswire.com

Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing's Syndrome | Illinois

December 31, 2021

CHICAGO--(BUSINESS WIRE)--Dec 30, 2021--

United States Xeris Biopharma Leslie Edwin Xeris Careconnection Paulr Edick Allison Wey

Source: wsiltv.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

P Gp Substrates News Today

Xeris Biopharma Announces Recorlev&#xAE; (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing's Syndrome | Illinois

PANTHERx Rare&#xAE; Selected by Xeris Pharmaceuticals to Distribute Recorlev&#xAE; (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome

PANTHERx Rare&#xAE; Selected by Xeris Pharmaceuticals to Distribute Recorlev&#xAE; (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome

Xeris Biopharma Announces U.S. FDA Approval of Recorlev&#xAE; (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing's Syndrome | Illinois

Explore More Categories

Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing's Syndrome | Illinois

PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome

PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome

Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing's Syndrome | Illinois